IHLAL
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
40
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Incannex Healthcare Limited - Option Expiring 22-Apr-2022 Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IHLAL
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IHLAL
N/A
IHLAL investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in IHLAL also invest in...
Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The firm is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The firm targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. The company is investigating the use of psilocybin-assisted psychotherapy to treat GAD.
🙌 Performance (5Yr p.a)
21.00%
📊 Share price
$0.04 AUD
NULL STOCK
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.79%
📊 Share price
$102.61 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
13.60%
📊 Share price
$80.02 AUD
🤖 TECHNOLOGY
🏭 INDUSTRIALS
🇦🇺 EX AUSTRALIA
📈 HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.24%
📊 Share price
$138.29 AUD
💸 FINANCIALS
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA